AstraZeneca third to announce effective vaccine

By , Special to the Daily Memphian Published: November 23, 2020 11:30 AM CT

LONDON (AP) — Pharmaceutical company AstraZeneca said Monday, Nov. 23, that late-stage trials showed its coronavirus vaccine was 70% effective, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than some of its rivals.

The results are based on interim analysis of trials in the United Kingdom and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalizations or severe cases of COVID-19 were reported in those receiving the vaccine.

AstraZeneca is the third major drug company to report late-stage results for a potential COVID-19 vaccine as the world awaits scientific breakthroughs that will bring an end to a pandemic that has wrought economic devastation and resulted in nearly 1.4 million confirmed deaths.


Moderna vaccine shows 94.5% effectiveness against COVID


Pfizer and Moderna last week reported preliminary results from late-stage trials showing their vaccines were almost 95% effective. But, unlike its rivals, the AstraZeneca vaccine doesn’t have to be stored at ultra-cold temperatures, making it easier to distribute, especially in developing countries.

“I think these are really exciting results,” Dr. Andrew Pollard, chief investigator for the trial, said during a news conference. “Because the vaccine can be stored at fridge temperatures, it can be distributed around the world using the normal immunization distribution system. And so, our goal … to make sure that we have a vaccine that was accessible everywhere, I think we’ve actually managed to do that.”


What Pfizer can learn in Tennessee when it comes to vaccine rollout


The Oxford-AstraZeneca vaccine is also cheaper.

AstraZeneca, which has pledged it won’t make a profit on the vaccine during the pandemic, has reached agreements with governments and international health organizations that put its cost at about $2.50 a dose. Pfizer’s vaccine costs about $20 a dose, while Moderna’s is $15 to $25, based on agreements the companies have struck to supply their vaccines to the U.S. government.

Topics

AstraZeneca

Comment On This Story

Become a subscriber to join the discussion.
Email Editions

Sign up for our morning and evening editions, plus breaking news.

Manage Your Email Subscriptions